



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 5 June 2023 (#20)

Confirm your intent to apply **ASAP**, but not later than **60 days** before the submission date.

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

To prepare an application can take **4-18 months**, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

Before starting your application, attend the **1) Generic Grant Writing Workshop** and then the **2) NIH Grant Writing Workshop**.

## Important Notices

**[NOT-HG-23-044](#) Notice of Intent to Publish a Notice of Funding Opportunity for Network of Genomics-Enabled Learning Health Systems (gLHS) – Clinical Sites (U01 Clinical Trial Required).** National Human Genome Research Institute ([NHGRI](#)) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications to support a network of genomic-enabled learning health systems (gLHS). These health systems will identify and improve approaches for clinical integration of genomic information in a virtuous cycle of implementation, assessment, refinement, and re-implementation. Specifically, this initiative would: 1) support 4-6 established or emerging gLHS clinical sites to share their genomic medicine implementation practices and identify those most suitable for cross-network implementation; 2) use these practices to conduct 2-4 network-wide pilot implementation projects and evaluate their impact; and 3) develop and refine successful gLHS implementation strategies as resources that can be broadly shared and adopted, including in resource-limited settings.

**[NOT-HG-23-045](#) Notice of Intent to Publish a Notice of Funding Opportunity for Network of Genomics-Enabled Learning Health Systems (gLHS) – Coordinating Center (U01 Clinical Trials Optional)** National Human Genome Research Institute ([NHGRI](#)) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications to support a network of genomic-enabled learning health systems (gLHS). These health systems will identify and improve approaches for clinical integration of genomic information in a virtuous cycle of implementation, assessment, refinement, and re-implementation. This NOFO will establish 1 gLHS coordinating center (CC) that will work with 4-6 clinical sites (CS) to form a gLHS Network that will share and develop current best practices for implementing, evaluating, refining, and re-implementing genomic medicine interventions.

## Parent Announcements

**[NOT-OD-23-105](#) Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities.** Current Key Dates  
*Expiration Date: May 8, 2023 Modified Key Dates Expiration Date: May 8, 2024*

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notice of Special Interest (NOSI)

**[NOT-DK-23-022](#) Administrative Supplements to Support Collaborations to Improve Data Interoperability/Re-use for Existing Type 2 Diabetes Relevant Data Sets.** The Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD) in NIDDK currently supports numerous data rich projects designed to collect an array of human data types with the goal of understanding the heterogeneity and pathogenesis of Type 2 Diabetes (T2D), and to develop appropriate prevention and treatment strategies. The goal of this Notice of Special Interest (NOSI) is to provide support through administrative supplements collaborations to improve interoperability/re-use for NIDDK supported T2D data sets and related resources such as repositories and knowledgebases. This initiative is aligned with the [NIDDK Strategic Plan for Research](#), which describes research opportunities aimed at developing innovative technologies and resources to expand data science to advance scientific progress and enhance health, and to utilize data science to improve clinical studies. This NOSI is soliciting administrative supplements from existing awardees funded by NIDDK's DDEMD. Projects are eligible to apply if they have at least one year of support remaining in the project period as of July 1, 2023. Application Due Date Thursday, July 11, 2023, by 5:00 PM local time of applicant organization for awards in August to September 2023.

**[NOT-MH-23-240](#) Administrative Supplements for COVID-19 Impacted NIMH Research.** The purpose of this Notice is to outline priorities for providing supplemental funding to investigators and institutions with active National Institute of Mental Health (NIMH) awards that experienced significant setbacks as result of the COVID-19 pandemic, which were unable to be resolved with non-monetary options (e.g., modification to the project or re-budgeting to accomplish aims). Applications will be accepted on a rolling basis **through April 1, 2026, 5:00 PM local time** of the applicant organization for consideration within that funding year. Applications received after April 1<sup>st</sup> in any fiscal year will be considered for funding in the next fiscal year.

**[NOT-MH-23-265](#) Mental Health Comorbidities in HIV Prevention and Treatment.** The National Institute of Mental Health (NIMH) is issuing this Notice to highlight interest in receiving grant applications focused on understanding and addressing the impact of mental health comorbidities, including mental health disorders, violence, and trauma, on HIV prevention and treatment outcomes. This NOSI is a reissue of [NOT-MH-20-013](#). It is strongly recommended that applicants review the NIMH Division of AIDS Research current Notices of Funding Opportunities (NOFO) (available on at <https://www.nimh.nih.gov/about/organization/dar/aids-related-funding-opportunity-announcements-foas>), and consult with a Program Officer before application submission.

## Notice of Funding Opportunity (NOFO)

### 1. International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-23-023](#)

**Type:** R01

**Application Due Date:** August 02, 2023; August 02, 2024; August 01, 2025. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to support applications for high-priority, regionally relevant infectious diseases research by international investigators in resource-constrained countries. Applicant organizations must be headquartered in foreign (non-U.S.) resource-constrained countries (i.e. low-income economies, lower-middle-income economies, and upper-middle-income economies by [World Bank Classification](#)). Applicant organizations headquartered in low- and lower-middle income economy countries are particularly encouraged to apply. Eligibility status of applicant organizations will be determined by the World Bank Classification list at the time of application submission.

**Budget:** NIAID intends to commit \$1,360,000 in FY 2024 to fund 7-8 awards. Application budgets should not exceed \$125,000 in direct costs per year, and should reflect the actual needs of the project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 2. NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-206](#)

**Type:** R34

**Application Due Date:** September 13, 2023 through to May 13, 2026. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** This Notice of Funding Opportunity (NOFO) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (<https://www.niaid.nih.gov/research/role>).

**Budget:** Application budgets are limited to \$150,000 direct costs. The scope of the proposed project should determine the project period. The maximum period is one year.

## 3. Enhancing Use of Harmonized Cognitive Assessment Protocol Data (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AG-24-032](#)

**Type:** R01

**Application Due Date:** October 02, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The purpose of this Notice of Funding Opportunity (NOFO) is to further our understanding of how different behavioral, social, cultural, environmental, and institutional factors affect the trajectory of cognitive aging and Alzheimer's disease (AD) and AD-related dementias (ADRD) and the experience of living with or managing AD/ADRD in different national or regional contexts. Specifically, NIA seeks to support (1) analyses of data from the Harmonized Cognitive Assessment Protocol (HCAP) from the U.S. or another country where HCAP data is available, or (2) cross-national analyses of HCAP data.

**Budget:** NIA intends to commit \$3,500,000 in fiscal year 2024 to fund 4-5 awards. Applications budgets are limited to \$500,000 in direct costs per year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 4. Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-MH-24-120](#)

**Type:** UG3/UH3

**Application Due Date:** October 18, 2023; October 18, 2024. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The purpose of this phased Notice of Funding Opportunity (NOFO) is to create a pipeline to accelerate the development and early validation of predictive tools and/or biomarkers to inform individual-level treatment selection among two or more existing therapeutics for depression. This phased inter-agency program will be milestone-based and provide support from multi-disciplinary teams to address scientific, technical, clinical, regulatory, and commercialization requirements. In the first phase (UG3), investigators are expected to identify potential tools and/or biomarker(s) that can predict whether a patient will differentially respond to one well-established depression treatment versus another. This could be accomplished using secondary analysis of data from completed clinical trials or using real-world clinical data, or by conducting small, efficient pilot feasibility studies to assess promising new tools or biomarkers to predict individual treatment response to a specific therapeutic for depression. In the second phase (UH3), investigators will conduct independent, prospective clinical trials to initially validate the utility of the tool/biomarker for predicting differential response to established treatments for depression. The overall goal of this NOFO is to support the testing of various tools/biomarkers as predictors of response to well-established depression treatments and halt the development of those tools that do not meet sufficient performance characteristics to justify further testing. Ultimately, tools that are successful in early stage studies could be further evaluated for future use in decision-making in clinical practice settings.

**Budget:** NIMH intends to commit a total of \$5,000,000 in FY 2024 to fund up to 10 awards. Application budgets are limited to \$500,000 in direct costs per year for the UG3 phase and up to \$1,500,000 in direct costs per year of the UH3 phase. Applicants may seek one-two years of funding for the UG3 phase and up to 5 years in total for the UG3/UH3 phase. The actual duration of individual projects will depend on successful achievement of milestones and conditions as described in Milestones Section of the program overview.

Research Development and Support Division (RDSD) & Grants Management Office (GMO)  
Faculty of Medicine and Health Sciences  
009 K<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Division for Research Development (DRD)  
Stellenbosch Campus  
2041 Krottoa Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105